Ad
related to: carnitine palmitoyltransferase ii deficiency treatment- Website For Patients
Visit this website if you are
a patient seeking information.
- Trials and Results
Learn about the first phase
3 pivotal trial program.
- Safety Data
Learn about the this pk deficiency
treatment's safety profile.
- Mechanism of Action
See how this pk deficiency
treatment works in your body.
- Website For Patients
Search results
Results from the WOW.Com Content Network
Carnitine palmitoyltransferase II deficiency, sometimes shortened to CPT-II or CPT2, is an autosomal recessively inherited genetic metabolic disorder characterized by an enzymatic defect that prevents long-chain fatty acids from being transported into the mitochondria for utilization as an energy source. The disorder presents in one of three ...
CPT2 together with carnitine palmitoyltransferase I oxidizes long-chain fatty acids in the mitochondria. Defects in this gene are associated with mitochondrial long-chain fatty-acid (LCFA) oxidation disorders and carnitine palmitoyltransferase II deficiency. [6] Acyl-CoA from cytosol to the mitochondrial matrix
Triheptanoin is used clinically in humans to treat inherited metabolic diseases, such as pyruvate carboxylase deficiency and carnitine palmitoyltransferase II deficiency. It also appears to increase the efficacy of the ketogenic diet as a treatment for epilepsy.
Palmitoylcarnitine is an ester derivative of carnitine involved in the metabolism of fatty acids.During the tricarboxylic acid cycle (TCA), fatty acids undergo a process known as β-oxidation to produce energy in the form of ATP. β-oxidation occurs primarily within mitochondria, however the mitochondrial membrane prevents the entry of long chain fatty acids (>C10), so the conversion of fatty ...
Carnitine palmitoyltransferase II, an important metabolic enzyme. Carnitine palmitoyltransferase II deficiency, a condition that prevents the body from converting certain fats into energy; Killarney Airport, CPT2 ICAO airport code, located in Killarney, Ontario, Canada
Carnitine-acylcarnitine translocase deficiency has an autosomal recessive pattern of inheritance. Carnitine-acylcarnitine translocase deficiency is a rare, autosomal recessive metabolic disorder that prevents the body from converting long-chain fatty acids into energy, particularly during periods without food. [ 1 ]
Carnitine palmitoyltransferase I deficiency has an autosomal recessive pattern of inheritance. Mutations in the CPT1A gene cause carnitine palmitoyltransferase I deficiency by producing a defective version of an enzyme called carnitine palmitoyltransferase I. Without this enzyme, long-chain fatty acids from food and fats stored in the body ...
Lipid metabolism defects: carnitine palmitoyltransferase I and II deficiency, deficiency of subtypes of acyl CoA dehydrogenase (LCAD, SCAD, MCAD, VLCAD, 3-hydroxyacyl-coenzyme A dehydrogenase deficiency), thiolase deficiency; Mitochondrial myopathies: deficiency of succinate dehydrogenase, cytochrome c oxidase and coenzyme Q10
Ad
related to: carnitine palmitoyltransferase ii deficiency treatment